Oncology Reviews

, Volume 4, Issue 4, pp 211–218

Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

Authors

  • Serena Meraviglia
    • Dipartimento di Biopatologia e Biotecnologie Mediche e ForensiUniversità di Palermo
  • Carmela La Mendola
    • Dipartimento di Biopatologia e Biotecnologie Mediche e ForensiUniversità di Palermo
  • Valentina Orlando
    • Dipartimento di Biopatologia e Biotecnologie Mediche e ForensiUniversità di Palermo
  • Francesco Scarpa
    • Dipartimento di Biopatologia e Biotecnologie Mediche e ForensiUniversità di Palermo
  • Giuseppe Cicero
    • Dipartimento di Discipline Chirurgiche ed OncologicheUniversità di Palermo
    • Dipartimento di Biopatologia e Biotecnologie Mediche e ForensiUniversità di Palermo
Review

DOI: 10.1007/s12156-010-0054-z

Cite this article as:
Meraviglia, S., La Mendola, C., Orlando, V. et al. Oncol Rev (2010) 4: 211. doi:10.1007/s12156-010-0054-z
  • 31 Views

Abstract

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.

Keywords

Vγ9Vδ2 T cellsHematologic malignanciesImmunotherapyCytokinesCytotoxicity

Copyright information

© Springer-Verlag 2010